## [# Politics Weigh On Health Care ETFs](/sections/news/politics-weigh-health-care-etfs) # Politics Weigh On Health Care ETFs Fears of Medicare-for-all are weighing on health care ETFs. Is this an opportunity? [![sumit](/sites/default/files/styles/author_image_icon/public/2023-03/Sumit_0.png?itok=SO-7S5SH "sumit")](/authors/sumit-roy) [By Sumit Roy ](/authors/sumit-roy) Apr 25, 2019 Edited by: Sumit Roy [ + Follow ](/etf/login) Share Email LinkedIn Facebook X (Twitter) googletag.cmd.push(function() { googletag.display('js-dfp-tag-article_page_302x26'); }); Loading In a year in which U.S. stocks have been roaring higher, it’s been hard to find pockets of the market that are doing poorly. The S&P 500 has surged 16.7% so far in 2019, sitting close to record highs, and each of the 11 stock market sectors is up—except one. The exception is health care. Measured by the [Health Care Select Sector SDPR Fund (XLV)](https://www.etf.com/xlv), health care slipped 0.26% in the year-to-date period through April 22, lagging far behind each of the other sectors. Utilities, the second-worst-performing sector, gained 9% in the same period, while every other sector was up double digits, including top-performing technology, with a 26.3% return. **Sector Returns** TickerFundYTD Return (%)[XLK](https://www.etf.com/xlk)[Technology Select Sector SPDR Fund ](https://www.etf.com/xlk)26.25[XLI](https://www.etf.com/xli)[Industrial Select Sector SPDR Fund ](https://www.etf.com/xli)21.91[XLE](https://www.etf.com/xle)[Energy Select Sector SPDR Fund ](https://www.etf.com/xle)20.57[XLY](https://www.etf.com/xly)[Consumer Discretionary Select Sector SPDR Fund ](https://www.etf.com/xly)20.42[XLC](https://www.etf.com/xlc)[Communication Services Select Sector SPDR Fund](https://www.etf.com/xlc)19.81[SPY](https://www.etf.com/SPY)[SPDR S&P 500 ETF Trust](https://www.etf.com/SPY)16.65[XLF](https://www.etf.com/xlf)[Financial Select Sector SPDR Fund ](https://www.etf.com/xlf)15.02[XLB](https://www.etf.com/xlb)[Materials Select Sector SPDR Fund ](https://www.etf.com/xlb)14.17[XLRE](https://www.etf.com/xlre)[Real Estate Select Sector SPDR Fund](https://www.etf.com/xlre)14.01[XLP](https://www.etf.com/xlp)[Consumer Staples Select Sector SPDR Fund ](https://www.etf.com/xlp)12.64[XLU](https://www.etf.com/xlu)[Utilities Select Sector SPDR Fund ](https://www.etf.com/xlu)8.96[XLV](https://www.etf.com/xlv)[Health Care Select Sector SPDR Fund ](https://www.etf.com/xlv)-0.26*Data measures total returns for the year-to-date period through April 22.* **Political Overhang** Health care’s stark underperformance compared with the broader stock market is the worst since 1993, according to Bloomberg. That was the year in which President Clinton tried to push a sweeping health care reform bill through Congress. The bill never became law, but at the time, it raised worries that profits for the health care industry could take a hit. A similar thing happened in 2010, when the Affordable Care Act, better known as Obamacare, actually became law thanks to Democrats’ control of the presidency and both chambers of Congress. Health care lagged the S&P 500 by 5.3% that year. Then again in 2016, during a bitter election year in which both leading candidates, Donald Trump and Hillary Clinton, bashed the industry for keeping drug costs too high, health care returned 4.4% less than the market. **Election Cycle Volatility** Clearly, as history suggests, volatility in [health-care stocks and ETFs](https://www.etf.com/topics/health-care-etfs) is not unusual in periods around major elections, or when far-reaching health care legislation has the potential to pass. “Volatility picks up for health care stocks around election cycles as sentiment moves around in reaction to different candidates’ plans for changing the health care sector, especially since health care benefits have been the key topic for voters since 2007,” said Brian Tanquilut, health care analyst at Jefferies. This year, that volatility has picked up early—more than a year and a half ahead of the U.S. elections— and vigorously, as certain candidates throw their support behind legislation that could completely transform the industry at the expense of health care firms. **Medicare For All** At the forefront of the movement to upend the health care status quo is Senator Bernie Sanders, who unveiled a “Medicare-for-All” bill earlier this month that is also being backed by several other Democratic presidential candidates. Medicare, in its current form, is a national health insurance program for the elderly. “This proposed piece of legislation would establish a national health insurance program to provide comprehensive protection against the cost of health care and health-related services,” explained Chris Meekins and Joseph Yanchunis, analysts at Raymond James. In other words, Medicare for all would establish a single-payer, government-run program that would eliminate most private insurance, say the analysts. **End Of Private Insurance?** If the Sanders bill were to pass, the effect on the health care industry would be profound. Medicare “is the low-cost payer to hospitals,” wrote Raj Denhoy and Anthony Petrone, medical device analysts at Jefferies. “If it becomes a bigger portion of the overall payor mix, hospitals will be under a lot of pressure to lower costs.” If “Medicare-for All” becomes the law of the land, the hospital industry could lose $800 billion over a decade; drug prices might be reduced by 30%; and the private insurance industry would be outlawed overnight, according to analysis by Raymond James’ Meekins and Yanchunis. It goes without saying that Medicare for all would be devastating for many health care stocks, and by extension, health care ETFs. **Less Than 1% Chance** The prospect of big changes to the health care industry might be scary for investors. But before you sell all your health care funds, understand that nothing is a done deal. The election is many months away, and there is no telling which presidential candidate will grab the Democratic nomination, let alone who will win the general election. That’s why Raymond James analysts believe there is less than 1% chance that Medicare for all actually becomes the law of the land in the next five years. If that’s the case, health care ETFs could end up being a bargain once the political dust settles. **Long-Term Value** Short-term movements aside, most analysts tend to agree that, barring sweeping changes to health care law in the U.S., the sector is a good long-term value after this year’s underperformance. For investors interested in potentially capturing that value, the aforementioned XLV is the obvious choice. The $17.4 billion ETF is the largest, most liquid health care fund on the market. However, for investors looking to take bolder bets on the segment, XLV may not be the best option. The actively managed $417 million [ARK Genomic Revolution ETF (ARKG)](https://www.etf.com/arkg) has trounced XLV so far this year, delivering a gain of 35.7% thanks to big bets on gene-related companies like Illumina, Invitae and Intellia Therapeutics. ***(Use our* *[stock finder tool](https://www.etf.com/etfanalytics/etf-stock-finder)* *to find an ETF’s allocation to a certain stock.)*** Stocks of insurance companies—poised to be the biggest losers if Medicare for all becomes law—aren’t found in ARKG. Similarly, biotech funds like the [ALPS Medical Breakthroughs ETF (SBIO)](https://www.etf.com/sbio), the [Virtus LifeSci Biotech Clinical Trials ETF (BCC)](https://www.etf.com/BBC) and the [SPDR S&P Biotech ETF (XBI)](https://www.etf.com/xbi) have done well, with double-digit returns. For a full list of the available health care ETFs and their year-to-date returns, see the table below: **Health Care ETF YTD Returns** TickerFundYTD Return (%)[LABU](https://www.etf.com/LABU)[Direxion Daily S&P Biotech Bull 3X Shares](https://www.etf.com/LABU)45.75[ARKG ](https://www.etf.com/arkg)[ARK Genomic Revolution ETF](https://www.etf.com/arkg)35.70[KURE ](https://www.etf.com/kure)[KraneShares MSCI All China Health Care Index ETF](https://www.etf.com/kure)31.71[CHIH ](https://www.etf.com/chih)[Global X MSCI China Health Care ETF](https://www.etf.com/chih)29.36[CHNA ](https://www.etf.com/chna)[Loncar China BioPharma ETF](https://www.etf.com/chna)25.44[SBIO ](https://www.etf.com/sbio)[ALPS Medical Breakthroughs ETF](https://www.etf.com/sbio)19.69[BBP ](https://www.etf.com/bbp)[Virtus LifeSci Biotech Products ETF](https://www.etf.com/bbp)18.51[UBIO](https://www.etf.com/ubio)[ProShares UltraPro Nasdaq Biotechnology](https://www.etf.com/ubio)18.40[BBC ](https://www.etf.com/bbc)[Virtus LifeSci Biotech Clinical Trials ETF](https://www.etf.com/bbc)18.36[XBI ](https://www.etf.com/xbi)[SPDR S&P Biotech ETF](https://www.etf.com/xbi)17.80[BTEC ](https://www.etf.com/btec)[Principal Healthcare Innovators Index ETF](https://www.etf.com/btec)16.52[BIB ](https://www.etf.com/bib)[ProShares Ultra NASDAQ Biotechnology](https://www.etf.com/bib)14.56[KMED ](https://www.etf.com/kmed)[KraneShares Emerging Markets Healthcare Index ETF](https://www.etf.com/kmed)12.26[FBT ](https://www.etf.com/fbt)[First Trust NYSE Arca Biotechnology Index Fund](https://www.etf.com/fbt)9.88[PBE](https://www.etf.com/pbe)[Invesco Dynamic Biotechnology & Genome ETF](https://www.etf.com/pbe)9.60[IBB ](https://www.etf.com/ibb)[iShares NASDAQ Biotechnology ETF](https://www.etf.com/ibb)8.46[BBH ](https://www.etf.com/bbh)[VanEck Vectors Biotech ETF](https://www.etf.com/bbh)8.33[IHI ](https://www.etf.com/ihi)[iShares U.S. Medical Devices ETF](https://www.etf.com/ihi)7.65[XPH ](https://www.etf.com/xph)[SPDR S&P Pharmaceuticals ETF](https://www.etf.com/xph)6.51[XHE](https://www.etf.com/xhe)[SPDR S&P Health Care Equipment ETF](https://www.etf.com/xhe)6.21[CNCR ](https://www.etf.com/cncr)[Loncar Cancer Immunotherapy ETF](https://www.etf.com/cncr)5.09[RYH ](https://www.etf.com/ryh)[Invesco S&P 500 Equal Weight Health Care ETF](https://www.etf.com/ryh)4.95[FTXH](https://www.etf.com/ftxh)[First Trust Nasdaq Pharmaceuticals ETF](https://www.etf.com/ftxh)4.55[PPH ](https://www.etf.com/pph)[VanEck Vectors Pharmaceutical ETF](https://www.etf.com/pph)3.91[IEIH ](https://www.etf.com/ieih)[iShares Evolved U.S. Innovative Healthcare ETF](https://www.etf.com/ieih)3.86[PTH ](https://www.etf.com/pth)[Invesco DWA Healthcare Momentum ETF](https://www.etf.com/pth)3.84[IHE ](https://www.etf.com/ihe)[iShares U.S. Pharmaceuticals ETF](https://www.etf.com/ihe)3.57[FXH](https://www.etf.com/fxh)[First Trust Health Care AlphaDEX Fund](https://www.etf.com/fxh)3.11[PSCH ](https://www.etf.com/psch)[Invesco S&P SmallCap Health Care ETF](https://www.etf.com/psch)1.95[JHMH ](https://www.etf.com/jhmh)[John Hancock Multifactor Healthcare ETF](https://www.etf.com/jhmh)1.59[IXJ ](https://www.etf.com/ixj)[iShares Global Healthcare ETF](https://www.etf.com/ixj)1.47[FHLC](https://www.etf.com/fhlc)[Fidelity MSCI Health Care Index ETF](https://www.etf.com/fhlc)1.35[VHT ](https://www.etf.com/vht)[Vanguard Health Care ETF](https://www.etf.com/vht)1.31[IEHS](https://www.etf.com/iehs)[iShares Evolved U.S. Healthcare Staples ETF](https://www.etf.com/iehs)0.74[IYH ](https://www.etf.com/iyh)[iShares U.S. Healthcare ETF](https://www.etf.com/iyh)0.48[RXL ](https://www.etf.com/rxl)[ProShares Ultra Health Care](https://www.etf.com/rxl)0.37[XLV ](https://www.etf.com/xlv)[Health Care Select Sector SPDR Fund](https://www.etf.com/xlv)-0.26[SLIM ](https://www.etf.com/slim)[The Obesity ETF](https://www.etf.com/slim)-0.60[PJP](https://www.etf.com/pjp)[Invesco Dynamic Pharmaceuticals ETF](https://www.etf.com/pjp)-1.82[RXD ](https://www.etf.com/rxd)[ProShares UltraShort Health Care](https://www.etf.com/rxd)-1.90[XHS ](https://www.etf.com/xhs)[SPDR S&P Health Care Services ETF](https://www.etf.com/xhs)-3.08[CURE ](https://www.etf.com/cure)[Direxion Daily Healthcare Bull 3x Shares](https://www.etf.com/cure)-4.58[IHF ](https://www.etf.com/ihf)[iShares U.S. Healthcare Providers ETF](https://www.etf.com/ihf)-6.18[PILL ](https://www.etf.com/pill)[Direxion Daily Pharmaceutical & Medical Bull 3X Shares](https://www.etf.com/pill)-8.51[BIS ](https://www.etf.com/bis)[ProShares UltraShort Nasdaq Biotechnology](https://www.etf.com/bis)-17.65[ZBIO](https://www.etf.com/zbio)[ProShares UltraPro Short Nasdaq Biotechnology](https://www.etf.com/zbio)-27.54[LABD ](https://www.etf.com/labd)[Direxion Daily S&P Biotech Bear 3X Shares](https://www.etf.com/labd)-48.06*Data measures total returns for the year-to-date period through April 22.* ​*Email Sumit Roy at* [*sroy@etf.com*](mailto:sroy@etf.com) *or follow him on Twitter [sumitroy2](https://www.etf.com/sumitroy2)* [ + Follow ](/etf/login) [ Sumit Roy Senior ETF Analyst ](/authors/sumit-roy) Sumit Roy is the senior ETF analyst for etf.com and author of (Don't) Invest Like a Pro. He creates a variety of content for the platform, including… [View Bio](/authors/sumit-roy) Related Topics [Equity](http://www.etf.com/topics/equity) [U.S.](http://www.etf.com/topics/us) [Sectors](http://www.etf.com/topics/sectors) [Active Management](http://www.etf.com/topics/active-management) [Alpha-Seeking](http://www.etf.com/topics/alpha-seeking)